Presentation of the Diabetes Complications Research

Our vision is to give people with diabetes a longer and better life, by preventing or delaying the development of diabetic late complications in, for example, kidneys and cardiovascular system.

Research field

Diabetes is the most common cause of chronic kidney failure, amputations and blindness, and significantly increases the risk of cardiovascular disease. Therefore, diabetes can have high costs for the individual with diabetes in terms of increased morbidity and mortality, and in addition it is expensive to treat for the society.

Fortunately, it is far from everyone who is affected by these complications, but we only partially understand why some people get complications and others go free. If we were able to better understand the background of the complications, we would also be able to better identify new treatments and methods for detecting people at risk as early as possible. Major advances have been made in the treatment of diabetes and risk factors that have been instrumental in reducing the incidence of late sequelae, but significant improvements are still needed.

We are therefore conducting studies of mechanisms that lead to complications, studies of new methods for detecting late sequelae, and treatment studies in which we try new treatments to prevent or slow down the development of complications.

The ambition

In our research, we want to extend the lives of people with diabetes with good years of life with a high quality of life by preventing late complications.
Early identification of people at particular risk of late complications using biomarkers, scans and other markers should help to initiate preventive treatment against the complications.
There is a need for intensive treatment of many risk factors, some of which have not yet been identified, but also an individualized treatment based on characteristics or profiles of the individual. Detailed understanding of which disease mechanisms are active in the individual can hopefully lead to better treatment with greater efficacy and fewer side effects.
We therefore investigate new treatments in clinical studies and combine them in some studies with biomarkers to target the treatment. The effect of treatment is assessed on biological endpoints, but also patient-reported effects are important. It is our ambition to involve people with diabetes in research at all levels, including examining preferences and working on shared decision making.


  • Kidney team (Marie Frimodt-Møller)
  • Clinical Physiology (Tine Willum Hansen)
  • Bioinformatics (Tarun Ahluwalia)
  • Intervention studies (Frederik Persson)
  • Neuropathy (Christian Stevns Hansen)
  • Person-centered care and treatment (Professor Kirsten Lomborg)


  • Joslin Diabetes Center
    Finn-Diane Helsinki University
  • University Medical Center Groningen
  • Mosaiques
  • Leuven Univ
  • Innsbruck University
  • Rigshospitalet Surgical, Nephrological and Clinical-Physiological Department
  • Herlev and Gentofte Hospital, Renal Medicine Department
  •  Roskilde Hospital Renal Medicine Department
  • and many more

Responsible editor